U.S. markets closed

Amgen Inc. (0R0T.L)

LSE - LSE Precio retrasado. Divisa en USD.
Añadir a la lista de seguimiento
243.76-3.37 (-1.36%)
Al cierre: 06:01PM GMT

Amgen Inc.

One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
805 447 1000
https://www.amgen.com

Sector(es)
Industria
Empleados a tiempo completo

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Robert A. BradwayChairman, CEO & Pres5.81M13.3M1963
Mr. Peter H. GriffithExec. VP & CFO2.66MN/D1959
Mr. Esteban SantosExec. VP of Operations2.61MN/D1968
Dr. David M. Reese M.D.Exec. VP of R&D2.79M419.8k1963
Mr. Murdo GordonExec. VP of Global Commercial Operations2.82MN/D1967
Ms. Linda H. LouieVP of Fin. & Chief Accounting OfficerN/DN/DN/D
Mr. Mike ZahigianSr. VP & Chief Information OfficerN/DN/DN/D
Mr. Arvind SoodVP of Investor RelationsN/DN/DN/D
Mr. Jonathan P. GrahamExec. VP, Gen. Counsel & Sec.N/DN/D1961
Ms. Nancy A. GrygielSr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance OfficerN/DN/D1968
Los importes son a partir de 31 de diciembre de 2021 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gestión corporativa

La calificación ISS Governance QuickScore de Amgen Inc. a partir del 1 de febrero de 2023 es 1. Las puntuaciones principales son Auditoría: 2; Junta: 8; Derechos del accionista: 1; Compensación: 1.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.